We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$425M
AUM Growth
-$23.3M
Cap. Flow
+$875K
Cap. Flow %
0.21%
Top 10 Hldgs %
49.03%
Holding
60
New
17
Increased
11
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$8.7M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$6.55M
3
GYRE icon
Gyre Therapeutics
GYRE
+$6.09M
4
CLDX icon
Celldex Therapeutics
CLDX
+$5.74M
5
VRDN icon
Viridian Therapeutics
VRDN
+$5.62M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$10.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.61M
4
SURF
Surface Oncology, Inc. Common Stock
SURF
+$9.24M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$8.51M

Sector Composition

Rank Sector Weight
1 Healthcare 82.31%
2 Miscellaneous 17.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STSA
26
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$5.14M 1.21%
904,225
+704,225
+352% +$4.27M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.28B
$5.12M 1.2%
500,000
– –
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.55B
$5.08M 1.2%
500,000
-400,000
-44% -$4.12M
EPIX
29
DELISTED
ESSA Pharma
EPIX
$5.08M 1.19%
+175,000
New +$4.07M
GYRE icon
30
Gyre Therapeutics
GYRE
$727M
$5.04M 1.18%
+133,333
New +$6.09M
VRDN icon
31
Viridian Therapeutics
VRDN
$2.6B
$5.01M 1.18%
+300,000
New +$5.62M
NUVB icon
32
Nuvation Bio
NUVB
$2.39B
$4.96M 1.17%
+500,000
New +$5.59M
CRIS icon
33
Curis
CRIS
$3.27M
$4.81M 1.13%
1,063
– –
BCYC
34
Bicycle Therapeutics
BCYC
$301M
$4.48M 1.05%
+150,000
New +$3.87M
KYNB
35
Kyntra Bio
KYNB
$34.6M
$4.34M 1.02%
+5,000
New +$5.32M
IMUX icon
36
Immunic
IMUX
$179M
$4.22M 0.99%
26,500
– –
IMVT icon
37
Immunovant
IMVT
$8.11B
$4.01M 0.94%
250,000
-50,000
-17% -$1.32M
SRRA
38
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.45M 0.81%
200,000
– –
NVAX icon
39
Novavax
NVAX
$1.69B
$3.17M 0.75%
+17,500
New +$3.49M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$2.62M 0.62%
265,000
-335,000
-56% -$5.19M
KDMN
41
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.33M 0.55%
+600,000
New +$2.75M
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$2.25M 0.53%
+30,000
New +$2.46M
CTIC
43
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.18M 0.51%
750,000
– –
DTIL icon
44
Precision BioSciences
DTIL
$206M
$2.07M 0.49%
+6,667
New +$2.33M
CLDX icon
45
PUT
Celldex Therapeutics
CLDX
$3.12B
$2.06M 0.48%
+100,000
New +$2.3M
CMRX
46
DELISTED
Chimerix, Inc.
CMRX
$1.93M 0.45%
+200,000
New +$1.84M
CASI
47
DELISTED
CASI Pharmaceuticals
CASI
$1.56M 0.37%
+65,000
New +$1.83M
APVO icon
48
Aptevo Therapeutics
APVO
$3.15M
– –
0
– –
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
$1.15M 0.27%
450,000
+250,000
+125% +$1.02M
KRRO icon
50
PUT
Korro Bio
KRRO
$180M
$950K 0.22%
+2,000
New +$3.89M
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ghost Tree Capital held 60 positions worth $425M, down 5.2% from $449M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ghost Tree Capital's Q1 2021 filing shows 17 new, 11 increased, 11 reduced and 10 closed positions. Its largest new stake was iShares Russell 2000 ETF: 30,000 shares worth $6.63M. The largest sale was Travere Therapeutics, an estimated $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q1 2021 buy was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
  • Ghost Tree Capital added most to Kura Oncology in Q1 2021, an estimated $8.7M increase.
  • Ghost Tree Capital's biggest Q1 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $10.6M.
  • Ghost Tree Capital fully exited Travere Therapeutics in Q1 2021, selling an estimated $12.9M.
  • Ghost Tree Capital's ten largest holdings make up 49% of its $425M portfolio in Q1 2021.
  • Ghost Tree Capital opened 17 new positions and closed 10 in Q1 2021.
  • Ghost Tree Capital's portfolio value fell 5.2% quarter-over-quarter to $425M.

Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.